2) RXI-109 retinal scarring: According to Dirk Haussecker (https://rnaitherapeutics.blogspot.de/), who owns 3% of RXI's outstanding shares - and who previously absolutely trashed RXI, says "Here, the self-delivering RNAi trigger technology is tested for the first time in the eye where for reasons of technical feasibility (more equal biodistribution throughout eye than in the skin) and clinical application I see the most potential for this technology"
3) Samcyprone: I expect positive results
4) RXI-231 (skin-lightener cosmeceutical): I hope, I hope, I hope (ie, we'll soon see...)